MARKSANS PHARMA
|
MARKSANS PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 9.22 | 8.40 | 6.92 | 5.88 | 4.51 |
| CEPS(Rs) | 11.45 | 10.28 | 8.59 | 7.00 | 5.66 |
| DPS(Rs) | 0.90 | 0.80 | 0.60 | 0.50 | 0.25 |
| Book NAV/Share(Rs) | 66.64 | 54.44 | 45.57 | 38.51 | 27.10 |
| Tax Rate(%) | 25.06 | 24.08 | 25.65 | 21.42 | 24.52 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.78 | 19.39 | 20.03 | 16.64 | 16.71 |
| EBIT Margin(%) | 19.25 | 18.77 | 18.99 | 17.00 | 16.53 |
| Pre Tax Margin(%) | 18.45 | 18.35 | 18.50 | 16.56 | 15.98 |
| PAT Margin (%) | 13.83 | 13.93 | 13.75 | 13.01 | 12.06 |
| Cash Profit Margin (%) | 17.07 | 16.97 | 17.00 | 15.55 | 14.95 |
| Performance Ratios | |||||
| ROA(%) | 11.85 | 12.93 | 12.93 | 13.78 | 12.94 |
| ROE(%) | 15.31 | 16.89 | 16.53 | 18.59 | 18.72 |
| ROCE(%) | 21.10 | 22.50 | 22.40 | 22.89 | 23.82 |
| Asset Turnover(x) | 0.86 | 0.93 | 0.94 | 1.06 | 1.07 |
| Sales/Fixed Asset(x) | 2.01 | 2.16 | 2.33 | 2.62 | 2.42 |
| Working Capital/Sales(x) | 1.38 | 1.59 | 1.55 | 1.53 | 1.83 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.50 | 0.46 | 0.43 | 0.38 | 0.41 |
| Receivable days | 71.16 | 65.99 | 69.35 | 72.63 | 78.56 |
| Inventory Days | 109.20 | 97.24 | 87.89 | 81.36 | 97.65 |
| Payable days | 91.82 | 91.59 | 87.70 | 85.31 | 93.88 |
| Valuation Parameters | |||||
| PER(x) | 17.04 | 26.48 | 21.89 | 11.99 | 10.10 |
| PCE(x) | 13.73 | 21.62 | 17.65 | 10.07 | 8.05 |
| Price/Book(x) | 2.36 | 4.08 | 3.33 | 1.83 | 1.68 |
| Yield(%) | 0.57 | 0.36 | 0.40 | 0.71 | 0.55 |
| EV/Net Sales(x) | 2.09 | 3.58 | 2.86 | 1.36 | 1.04 |
| EV/Core EBITDA(x) | 9.02 | 15.68 | 12.23 | 6.32 | 5.18 |
| EV/EBIT(x) | 10.54 | 18.22 | 14.32 | 7.27 | 6.08 |
| EV/CE(x) | 2.02 | 3.77 | 2.97 | 1.41 | 0.94 |
| M Cap / Sales | 2.41 | 3.84 | 3.15 | 1.72 | 1.25 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 12.51 | 20.46 | 17.56 | 24.23 | 8.33 |
| Core EBITDA Growth(%) | 14.07 | 17.68 | 27.69 | 32.55 | -13.16 |
| EBIT Growth(%) | 13.39 | 18.61 | 25.36 | 35.48 | -17.47 |
| PAT Growth(%) | 9.79 | 21.51 | 18.68 | 42.02 | -21.68 |
| EPS Growth(%) | 9.81 | 21.32 | 17.80 | 30.32 | -21.77 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 |
| Current Ratio(x) | 5.17 | 4.62 | 4.78 | 4.91 | 3.22 |
| Quick Ratio(x) | 3.32 | 2.85 | 3.19 | 3.49 | 2.11 |
| Interest Cover(x) | 24.24 | 44.22 | 38.80 | 37.99 | 30.31 |
| Total Debt/Mcap(x) | - | - | - | 0.01 | 0.02 |
Compare Financial Ratios of peers of MARKSANS PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MARKSANS PHARMA | ₹12,193.3 Cr | 4.2% | 2.1% | 14.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹466,431.0 Cr | -2.3% | 3% | 12.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹220,115.0 Cr | 2.9% | 22.7% | 25.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,853.0 Cr | -2.7% | 2% | 33.9% | Stock Analytics | |
| CIPLA | ₹119,158.0 Cr | 0.1% | 3% | -7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,074.4 Cr | 2.4% | -12.9% | -9.1% | Stock Analytics | |
MARKSANS PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MARKSANS PHARMA | 4.2% |
2.1% |
14.6% |
| SENSEX | 1.3% |
1% |
-2.9% |
You may also like the below Video Courses
